Filter by year:

Pattinson R, Trialonis-Suthakharan N, Pickles T, Austin J, FitzGerald A, Augustin M, Bundy C.

We developed the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure in partnership with patients. It has strong evidence of content validity, structural validity, internal consistency, acceptability, and feasibility.

Publication year:2024
Journal:Br J Dermatol.

Pattinson R, Trialonis-Suthakharan N, Pickles T,  Austin J, FitzGerald A, Augustin M, Bundy C.

To examine the factor structure of PRIDD, determine the definitive selection of items for each subscale, and establish structural validity and internal consistency through classical and modern psychometric methods.

Publication year:2024
Journal:Br J Dermatol.

Trialonis-Suthakharan N, Pattinson R, Tahmasebi Gandomkari N, Austin J, Janus C, Courtier N, Hewitt RM, Bundy C, Augustin M.

The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing the new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure. PRIDD measures the impact of dermatological conditions on the patient's life.

Publication year:2024
Journal:J Eur Acad Dermatol Venereol.

Trialonis-Suthakharan N, Pattinson R, Tahmasebi Gandomkari N, Austin J, Janus C, Courtier N, Hewitt RM, Bundy C, Augustin M.

The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing a patient-reported measure of the impact of dermatological disease on the patient's life called Patient Reported Impact of Dermatological Diseases (PRIDD). We developed a list of 263 potential impact items through a global qualitative interview study with 68 patients. We next conducted a Delphi study to seek consensus on which of these items to prioritize for inclusion in PRIDD. This study aims to explore patterns in demographic (e.g. country) and clinical variables (e.g. disease group) across the impacts ranked as most important to European dermatology patients.

Publication year:2023
Journal:J Eur Acad Dermatol Venereol.

Pattinson R, Trialonis-Suthakharan N, Hewitt RM, Valencia López MJ, Tahmasebi Gandomkari N, Austin J, FitzGerald A, Courtier N, Augustin M, Bundy C.

The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing a patient-reported measure of the impact of dermatological disease on the patient's life called Patient Reported Impact of Dermatological Diseases (PRIDD). We developed a list of 263 potential impact items through a global qualitative interview study with 68 patients. We next conducted a Delphi study to seek consensus on which of these items to prioritize for inclusion in PRIDD. This study aims to explore patterns in demographic (e.g. country) and clinical variables (e.g. disease group) across the impacts ranked as most important to European dermatology patients.

Publication year:2023
Journal:Front Med (Lausanne)

Pattinson R, Hewitt RM, Trialonis-Suthakharan N, Chachos E, Courtier N, Austin J, Janus C, Augustin M, Bundy C.

Existing patient-reported outcome measures cannot comprehensively capture the full impact of living with a dermatological condition. The aim of this study was to develop a conceptual framework on which to build a new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure.

Publication year:2022
Journal:Acta Derm Venereol.

Pattinson RL, Trialonis-Suthakharan N, Gupta S, Henry AL, Lavallée JF, Otten M, Pickles T, Courtier N, Austin J, Janus C, Augustin M, Bundy C.

By relying on data from existing patient-reported outcome measures of quality of life, the true impact of skin conditions on patients’ lives may be underestimated. This study systematically reviewed all dermatology-specific (used across skin conditions) patient-reported outcome measures and makes evidence-based recommendations for their use.

Publication year:2021
Journal:Acta Derm Venereol.